Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CFD | P00746 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654930 | 0.83 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1MAPTCFD | |
| SCHEMBL31458333 | 0.80 | TAOK3 (0.67) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL14422175 | 0.80 | TAOK3 (0.67) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL5654189 | 0.79 | TAOK3 (0.62) | ALDH1A1KMT2AMEN1HTTLMNA | |
| SCHEMBL5654015 | 0.79 | KMT2A (0.51) | ALDH1A1KMT2AMEN1HTTLMNA | |
| SCHEMBL29131611 | 0.75 | HTT (0.60) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL29131608 | 0.75 | HTT (0.60) | ALDH1A1KMT2AMEN1MAPTHTT | |
| SCHEMBL29131630 | 0.74 | OPRK1 (0.59) | ALDH1A1KMT2AMEN1CFDHTT | |
| SCHEMBL29131632 | 0.74 | OPRK1 (0.59) | ALDH1A1KMT2AMEN1CFDHTT | |
| SCHEMBL14335070 | 0.74 | HTT (0.63) | ALDH1A1KMT2AMEN1HTTTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | claimed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | TAOK1, TAOK3, MAP3K6 | ALDH1A1 4424/4885KMT2A 2240/4885MEN1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.